HIGHOutside partySupplier
single-source components
“10-K Item 1: 'certain materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements'”
BSX · Concentration risk · 10-K extracted
Boston Scientific (BSX) concentration risks
Updated
The most significant concentration Boston Scientific discloses is single-source components, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Boston Scientific’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH1
MEDIUM2
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
36%
international net sales
“10-K Item 1A: 'International net sales accounted for 36 percent of our global net sales in 2025'”
MEDIUMBuilt-inProduct / Revenue mix
FARAPULSE
“10-K Item 1: 'FARAPULSE™ PFA System ... the predominant component of our Electrophysiology business unit and revenue'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile spans supply, geographic, and product dimensions. The supply-side exposure carries the highest disclosed size: certain materials and components are purchased from single sources, a high-share dependency where the absence of qualified alternatives reflects quality requirements, regulatory approval constraints, and cost considerations rather than a simple procurement preference. A disruption at any such sole-source supplier would require qualifying a replacement — a time-intensive process in a regulated medical device environment — making this the most acute idiosyncratic risk in the profile. International net sales accounted for 36% of global net sales in 2025, a moderate geographic concentration by disclosed size and structural in character. This reflects where the company's hospital and procedure volumes sit globally; the exposure is diffuse across many countries rather than concentrated in one, limiting the tail risk to broad international market conditions or broad regulatory changes rather than a single country event. The FARAPULSE system is identified as the predominant component of the Electrophysiology business unit and revenue, a moderate product concentration by disclosed size. Because its share of the broader company's revenues is not quantified cleanly in the disclosures, the filing treats it qualitatively as a dominant driver within one division. On balance, the supply dependency is the most distinctive exposure — a structural fragility common to medtech companies that is worth tracking for any regulatory or operational disruptions at key component suppliers. The geographic and product exposures are moderate features that reflect the company's commercial composition rather than single-name risks.
For the engine’s reasoning on BSX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| BSX● | Boston Scientific Corporation | 1 | 2 | 0 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AXGN | AxoGen, Inc. | 0 | 0 | 0 | 0 |
| BIO | Bio-Rad Laboratories, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.